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Breaking Life Expectancy into Small Pieces 
 
Andrey Ugarte1 
Onofre Alves Simões2,3 
Abstract 
Understanding mortality patterns and how they evolve in time has always been a 
challenging subject and many researchers have worked on it. We wish to enhance existing 
knowledge on the topic, by decomposing the effects on mortality of more than 400 combinations 
of “age class/Mortality Chapter”, in three countries with different characteristics and for a period 
of 44 years. Using classic decomposition methods, it is possible to observe a steady increase in Life 
Expectancy at birth and a decrease in the Gender Gap, identifying the main contributors to the 
phenomena in terms of “age class/Mortality Chapter”. Another finding is the existence of important 
similarities among countries.  
 
Keywords: Life Expectancy, Mortality Chapters, Human Mortality and Cause of Death Databases, 
France, Czech Republic, USA.   
 
1. Introduction 
Understanding and explaining the sources of change in demographic indicators such as life 
expectancy at different ages has been in the interest of the scientific community for a long time. 
However, the topic has gained relevance now more than ever, due to the financial difficulties that 
have affected, or are expected to affect, pension fund schemes and social security systems in 
general. Because of this, attention has increasingly turned to better understanding mortality, the 
patterns shown in the past, and how they have been evolving in time, as a way of enhancing the 
scientific knowledge that will enable the community to better predict the future.  
Contributions of age and causes of death to life expectancy at birth (LE) can be calculated with 
decomposition methods (Andreev, Shkolnikov and Begun, 2002; Arriaga,1984, 1989; Das Gupta, 
1978). This approach has been widely used for various purposes, in particular, to research the 
effects on mortality of inequalities in socioeconomic conditions and access to health care, in 
different countries and regions (Agyepong et al., 2017; Bergeron-Boucher, Ebeling & Canudas-
Romo, 2015; Khang, Yang, Cho, Choi-Jung & Yun, 2010; Liu et al., 2016; Martikainen, Valkonen 
& Martelin, 2001; Martikainen, Makela, Peltonen & Myrskyla, 2014; Mondal & Shitan, 2014; 
Murwirapachena & Mlambo, 2015; Preston & Stokes, 2012; Shkolnikov, Andreev, McKee & Leon, 
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2013; Tarkiainen, Martikainen, Laaksonen & Valkonen, 2012; Wang et al., 2016; Yang, Khang, 
Chun, Harper & Lynch, 2012). Many other studies focus on the gender gap or other life expectancy 
issues, again in different parts of the world (Al-Ramadhan, 2008; Auger, Feuillet, Martel, Lo, Barry 
& Harper, 2014; Auger, Harper, Barry, Trempe & Daniel, 2012; Hosseinpoor, Lee, Lynch, Mathers 
& Abou-Zahr, 2012; Le, Ren, Shen, Li & Zhang, 2015; Rosella et al., 2016; Simmons, 2018; 
Trovato & Heyen, 2006; Trovato & Lalu, 1997; Trovato & Odynak, 2011; Vaupel & Romo, 2002; 
Waldon, 1983; Waldon, McCloskey & Earle, 2005; Yang, Khang, Chun, Harper & Lynch, 2012).  
In these works a decomposition of age and cause-specific mortality contributions to changes in life 
expectancy is performed. In our work, we apply the same methodology to create deeper knowledge 
on the dynamics behind life expectancy changes, not only because the analysis covers a very long 
period of time, but mostly because more than 20 age groups and 20 mortality chapters, as defined 
by the International Classification of Diseases, are under study. Three developed countries with 
significant historical differences with respect to mortality (France, Czech Republic and the United 
States) haven been chosen as case studies, to make direct comparisons possible. The research 
focuses not only on quantifying the changes in LE, but also on estimating simultaneously the 
contributions attributable to each of the different age groups and mortality chapters, in an 
exhaustive and in depth way and for over four decades. We expect our paper to enhance the 
understanding of mortality and longevity differences and their origin, the evolution of the observed 
patterns as time goes by, and the historical change in the decomposition of these patterns.  
In the following sections, we analyze in depth and for a 42-year period the changes in LE. To 
achieve this, mortality variations are decomposed considering age, cause of death (CoD) and the 
relationship between them for different nations, selected because of three major reasons: they 
belong to the small group of countries with CoD information available in the Human Mortality 
Database (HMD); they cover the entire range of gross national income of this group; and they have 
populations with very different sizes. 
The information available in the Cause of Death Database (CoDD) goes from 1959 to 2013 for 
USA, 1958 to 2015 for France, and 1968 to 2015 for Czech Republic.  In order to make the results 
comparable, a common time interval is necessary. Furthermore, it was important to break the 
timeline in three shorter periods of the same length, to better capture the evolution of the 
phenomenon in study. As a result, the analysis goes from 1970 to 2013, dividing the time horizon 
from 1970 to 1984, from 1985 to 1998, and from 1999 to 2013.   
 
2. Background, Data and Method 
In general, the concept of life expectancy is one of the most popular to use when analyzing 
mortality, so it is normally taken as an indicator of human health due to its capacity to “summarize 
mortality in a single measure” (Auger, Feuillet, Martel, Lo, Barry and Harper 2014). In this sense, 
whether a researcher uses this indicator or any other, it has become evident that mortality 
improvements are real, leading people to live longer.   
Global LE for both sexes went from 66.5 years in 2000 to 72 years in 2015, (World Health 
Organization, 2019). According to United Nations (2019), it increased from 64.2 years in 1990 to 
72.6 years in 2019 and is expected to increase further to 77.1 years in 2050. While considerable 
progress has been made in closing the longevity differential between countries, large gaps remain.  
In 2019, LE in the least developed countries lags 7.4 years behind the global average, due largely 
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to persistently high levels of child and maternal mortality, as well as violence, conflict and the 
continuing impact of the HIV epidemic. Moreover, the number of people in the world who were 
60 or older has doubled when compared to 1980, and it is expected that by 2050 16% of the world 
population will be aged 65 or more (9% in 2019), i.e., by 2050 one in six people in the world will 
be over age 65 (16%), up from one in 11 in 2019 (9%), cf United Nations (2019).  
Following the same sources, regions where the share of the population aged 65 years or over is 
projected to double between 2019 and 2050 include Northern Africa and Western Asia, Central and 
Southern Asia, Eastern and South-Eastern Asia, and Latin America and the Caribbean. By 2050, 
one in four persons living in Europe and Northern America could be aged 65 or over. In 2018, for 
the first time in history, persons aged 65 or above outnumbered children under five years of age 
globally. The number of persons aged 80 years or over is projected to triple, from 143 million in 
2019 to 426 million in 2050.  
Furthermore, there seems to be a growing interest in the so-called “Blue Zones”, see Poulant, 
Buettner and Pes (2019), a selected group of places in the world with an extraordinarily high 
concentration of people living to ages over 100. According to the World Economic Forum (2017), 
Loma Linda in California (USA), Nicoya in Costa Rica, Sardinia in Italy, Icaria in Greece, and 
Okinawa in Japan are the members of this selective group that has driven researchers to try to 
understand the factors behind these high longevity levels.  
In this context, actuaries have become protagonists in the search of solutions and contingency plans 
for countries to face the issues associated to having a much older population. The uncertainty of 
not knowing exactly how much further the improvements in mortality may go, and how deep the 
financial cost of the phenomenon may be, has received the name of Longevity Risk, one of the key 
factors in the actuarial scene nowadays. The Actuarial Association of Europe (2019) found that in 
this continent, in the context of the aging population, “costs are projected to rise in every country 
on health and long-term care spending. These projections depend not only on the population 
projections but also on how life expectancy increases translate into healthy life expectancy and how 
the demand for health and long-term care services evolve”. Better understanding the drivers behind 
this extended longevity helps shed some light on the possibilities for the future, which allows 
systems to make more informed decisions.   
To analyze mortality information from the HMD and CoDD, a programmed tool has been 
developed, the Mortality Analysis Calculator (MAC). MAC, which was created by Ugarte A for 
the Department of Research of the Society of Actuaries, proved to be a very effective instrument. 
One of the main features of the Mortality Analysis Calculator is that it decomposes the changes in 
a mortality indicator by the contributions attributable per age group and mortality chapter, when 
applicable. In order to decompose the variations, the tool makes use of algorithms already present 
in the literature, relying mostly on the seminal contributions of Andreev, Shkolnikov and Begun 
(2002) and Arriaga (1984, 1989). 
 
2.1 Decomposition of the changes in a mortality indicator per age group 
Consider the changes between years 𝑡1 and 𝑡2 (𝑡2 > 𝑡1) in a mortality indicator estimated for a 
specific age a.  When computing the attributable contribution to changes associated to an age/age 
group, the algorithm presented by Andreev, Shkolnikov and Begun (2002) is used. The original 
paper presents the formula to decompose changes between two periods in time, but in general it 
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applies to compare two different “experiences” in an indicator - whether the change comes from 
time, gender or an ethnic group, for example. The notation presented here is slightly different from 
that used in the original paper, but the underlying principles remain intact. 
Denote a mortality indicator - life expectancy in this case - for age a as 𝐼𝑛𝑑𝑎. Then the attribution 
of change in the mortality indicator between years 𝑡1 and 𝑡2 at age a associated to a contributing 
age x is 
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In the calculations that follow (2) and (3) will be used. 
 
2.2 Decomposition of changes associated to causes of death 
In this paper we also compute the contribution of the evolution of causes of death in the mortality 
indicators. Similar to the previous section, consider 𝛿𝑥
𝑎  as the contribution to change attributable to 
age x in the mortality indicator at age a between years 𝑡1 and 𝑡2. Assume that the environment is 
affected by n diseases, so that we denote the change in the indicator at age a between years 𝑡1 and 
𝑡2 due to disease i (𝑖 = 1,2,3,… , 𝑛) as 𝛼𝑎
𝑖 2−1. Following the reasoning in Arriaga’s method, the 
change associated with disease i is  
𝛼𝑎
























𝑖  denotes the mortality rate associated with disease i for age x during year 𝑡𝑘. Similarly, 
𝑞𝑥
𝑘 represents the total mortality rate for age x (i.e. including all n diseases) during year 𝑡𝑘. 
Analyzing the formula, it becomes evident that it distributes the changes in the indicator attributable 




𝑖  is just the proportion of the overall change in mortality for age x that was registered between 
times 𝑡1 and 𝑡2 that is attributable to cause i.  
The underlying assumption is that the contributions to changes associated to a cause are directly 
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3. Breaking Life Expectancy at Birth from 1970 to 2013 
LE shows remarkable evolution in France, Czech Republic and the United States. In all three 
countries the values of the indicator have increased as mortality dynamics evolve at different stages 
of human life and the effect of diseases vary in time. We will present next the decomposition of 
changes in LE per age group and the contributions attributable to the different mortality chapters, 
calculated using equations (2)-(5).  
 
3.1 Life Expectancy at Birth in France 
France has experienced a sustained growth in LE in the period of interest. This indicator went from 
68.4 years for males and 75.8 years for females in 1970 to 78.8 years and 85.1 years (respectively) 
in 2013. This represents a change of 10.4 years for males and 9.3 years for females in the entire 
period. These changes, however, did not occur in a “uniform” manner and can be explained in 
different ways along this time interval.  
3.1.1 1970-1984  
During this term, females experienced a bigger increase in their LE, and registered a total change 
of 3.54 extra years against 2.77 extra years for males. Per age group, the changes experienced in 
LE during this period are characterized by a very important increase due to mortality changes at 
early ages. For example, the contribution to the change attributed to the first year of life alone 
amounts to around 29% of the total change for males and 19% for females. In general, during this 
time period, when considering the changes attributable to ages younger than 65, mortality changes 
in these age groups contributed with almost 64% of the total increase (1.76 years) in the case of 
males whereas for females they amount to 51% (or 1.81 years). In the case of males, estimations 
show that only 1 year is attributable to changes in mortality at ages 65 and older (out of the 2.77 
years), while the number increases to 1.73 years when considered the total change of 3.54 years for 
females. From this information, it seems that women at older ages saw a much more significant 
improvement in their mortality prospects than men, who were experiencing a greater mortality 
enhancement at young ages. 
When analyzing the results and estimated changes attributed to the different mortality chapters, 
estimations show that the most relevant increment in life expectancy, for both genders, took place 
due to improvements in Cerebrovascular Diseases (Mortality Chapter IX). The changes in mortality 
due to this group of diseases represented an estimated improvement in LE of half a year for males 
and 0.64 years for females, between 1970 and 1984. Changes in mortality due to Heart Diseases 
(Mortality Chapter VIII) also played a central role in improving the indicator for both genders, but 
the effect is much higher in the case of females since it is estimated that women gained over half a 
year in LE (against 0.35 years for males). Similar results are obtained for Mortality Chapter XIX, 
Ill-defined or Unknown Causes, registering an improvement of 0.52 years for females and 0.38 
years for males.   
Moreover, Mortality Chapter XX - External Causes - including death due to accidents, homicides, 
poisoning, and the like, contributes considerably to the improvement in LE for men (0.34 years), 
but not for women (0.14 years). Finally, it is worth noting that results show an important decrease 
in LE for males due to Chapter II, Malignant Neoplasm, which caused an estimated loss in life 
expectancy of 0.55 years for men. Table A.1 in the annex shows all the details of the composition 
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of changes in life expectancy per cause of death. Sources of all figures and tables: Human Mortality 
Database, Cause of Death Mortality Database and MAC. 
 
Fig. 1 Changes in LE per CoD and Age, 1970-1984 (France, males vs. females) 
 
Figure 1 shows the estimated changes in LE per mortality chapter for the time interval being 
analyzed. The overall size of the bars represents the total variations estimated (axis y) for the 
mortality chapters (axis x). Every bar is divided in smaller segments with changing colors, 
representing where the overall change comes from in terms of contributing age groups. When a 
particular bar has a section in both the positive and negative quadrants, it shows that some ages 
contributed to a decrease in life expectancy for that mortality chapter whereas other age groups 
contributed to a gain. An example of this is Mortality Chapter XIX for females (with an overall 
gain of 0.525 years).   
3.1.2 1985-1998 
Contrary to what happened in the previous term, from 1984 to 1998 LE increased more for males 
than for females in France (with increments of 3.58 years for men and 3.06 years for women). The 
variation in LE attributable to each age group suffered several changes in structure: the contribution 
attributable to the first year of life decreased greatly in both absolute and relative numbers and 
represented less than 9% of the overall change in both genders. Moreover, between 1984 and 1998, 
the structure of changes is inverted per gender: the total change in LE for men coming from ages 
younger than 65 consists of 61% (2.18 years) of the total variation whereas 39% comes from ages 
older than 65. For women, it is the opposite, since 37% of changes (1.14 years) come from age 
groups younger than 65 and 63% from seniors.  
Regarding gains and losses in LE, we can see that from 1984 to 1998 France experienced, with 
great success, improvements in the treatment of diseases of the Circulatory System, which caused 
Mortality Chapter VIII to improve the indicator in 0.72 and 0.73 years for men and women, 
respectively. This puts in evidence an improvement in this cause of death much more significant 
than the one registered in the previous 14 years. The estimated increases in LE attributable to 
Cerebrovascular Diseases, which had registered a very prominent role in the previous term for both 
genders, continue to be relevant. In this period, this mortality chapter placed itself as the second 
and third main cause contributing to the enhanced indicator, for women and men. The estimations 
of gains due to this chapter yield half a year increment in LE for males and 0.66 years for females. 
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The mortality experience registered during this period also suggests important improvements in 
deaths caused by external causes, completing the top 3 contributors per mortality chapter. In this 
case, the gain years in life expectancy are more relevant for men than for women. These three 
causes of death are responsible for about 52% and 59% of the overall change in life expectancy 
during this period. Figure 2 shows this and other results. 
 
Fig. 2 Changes in LE per CoD and Age, 1985-1988 (France, males vs. females) 
 
3.1.3 1999-2013 
From 1999 to 2013, once again, the French population saw an important improvement in their LE. 
By the end of this period, like in the previous term, French men experienced a more significant 
increase than French women - men improved their LE in 4.05 years whereas women did so by 2.7 
years. Moreover, not only did men see a more prominent improvement in the indicator for the 
second consecutive term, but also the difference when compared with the gains in the case of 
women are much more notable: 1.35 years higher than that of French women (as opposed to half a 
year in the previous term). This certainly contributed to a reduction in the gender gap.  
The changes in LE during this period confirm the tendency detected previously: the improvements 
attributable to young ages start to lose relative importance as the mortality improvements start to 
come from the longevity of the elderly. During these 14 years, only 3% of the variation is 
attributable to changes in mortality of newborns for males (4% for females) whereas ages younger 
than 65 contributed with 47% of the overall change in the case of males and 30% in the case of 
females. Moreover, the variations attributable to senior ages amount to 2.1 years for males and 1.8 
years for females. In this sense, the change in the structure becomes more relevant in the case of 
French men as they seem to keep up better with female mortality at older ages. 
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During these years, life expectancy was primarily improved due to the influence of Mortality 
Chapter II, Malignant Neoplasm, which generated an improvement of 1.14 years in LE for men. 
The evolution of mortality due to Heart Diseases continued to affect positively life expectancy for 
both genders (with an estimated attribution of 0.89 years of increase in the indicator for men and 
0.78 years for women). Deaths due to external causes (Mortality Chapter XX) also helped to 
increase LE. Improvements related to Respiratory Diseases started to be more prominent during 
this term whereas causes such as Mental Disorders and Nervous System Disorders (Mortality 
Chapters VI and VII) caused subtle decreases in life expectancy.  
 
Fig. 3 Changes in LE per CoD and Age, 1999-2013 (France, males vs. females) 
 
3.2 Life Expectancy at Birth in Czech Republic 
In the case of Czech Republic, LE increased 9.03 years for males and 8.09 for females between 
1970 and 2013, going from 66.04 years and 73.99 years for males and females, respectively, to 
75.07 and 81.08 years. The causes of these variations, like in the case of France, seem to vary in 
time as mortality evolves per age and cause of death. 
3.2.1 1970-1984 
The change in LE in Czech Republic from 1970 and 1984 was very similar for both genders and 
reached 1.3 years in the case of males and 1.51 for females. Around a year of the change is estimated 
to have been generated by mortality changes in age groups younger than 65, which causes age 
groups over 65 to contribute in a much less significant manner during these years.  
Mortality improvements in respiratory diseases are estimated to be among the main drivers of the 
increase for Czech Republic during this period for both genders, generating an estimated gain in 
LE of half a year for males and 0.43 years for females. Another main cause of death contributing 
to the enhancement of the indicator is also shared by both genders: mortality changes originating 
in Mortality Chapter XVII, Conditions of the Perinatal Period, which increased life expectancy in 
0.36 and 0.33 years for males and females. All this variation is attributable to age 0. Improvements 
related to deaths caused by accidents, homicides, suicides, poisonings and the like (as defined in 
Mortality Chapter XX) contributed also in a great manner. This chapter is estimated to have 
generated 0.63 extra years of LE in the case of males (being the main cause explaining the increase 
in this case) and 0.19 extra years for females. Some chapters, however, are estimated to cause losses 
in LE for both genders during this time interval. Among them one finds Malignant Neoplasms and 
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Deaths related to Other Circulatory Diseases (Mortality Chapter X), estimated to have contributed 
to a loss in LE of 0.16 (males) and 0.1 years (females).  
 
Fig. 4 Changes in LE per CoD and Age, 1970-1984 (Czech Republic, males vs. females) 
 
3.2.2 1985-1998 
Mortality improvements were much more significant during this fourteen-year period, which lead 
to a life expectancy increase of 3.71 years for males and 3.49 years for females. Again, mortality 
improvements for newborns are estimated to be the main driver in these changes, generating an 
estimated attributable LE of 0.72 years for males and 0.55 years for females. Despite this fact, age 
groups younger than 65 became, in relative terms, less “important” when compared to the previous 
period. Nevertheless, they continued to be the main driver in the change and their absolute 
contributions increased, generating 2.42 and 1.69 extra years in LE for men and women, 
respectively. This means that the contributions of changes in ages 65 and older represented only 
35% of the variation for men but amount to 51% for women.  
When analyzing the changes per mortality chapter, the estimated main contributors seem to be 
different from the ones in the previous period. In the case of males, mortality improvements in 
causes of death included in Mortality Chapter VIII, Heart Diseases, are the most relevant: they are 
estimated to have contributed with 1.10 years of extra LE. These improvements are registered 
mostly in ages from 45 to 74 years old. The influence of these groups is estimated to explain 0.83 
years of the overall gains in this mortality chapter, showing that death rates associated to these 
causes improved greatly for adults mostly. Improvements in Cerebrovascular Diseases also seem 
to be central in the increase in LE. Their effect for men amounts to a gain of 0.67 years in the 
indicator. Respiratory diseases are also a major contributor in this case, generating 0.38 extra years 
of LE for males.  
In the case of women, mortality improvements in Cerebrovascular Diseases are considered to be 
the main driver of the improvement with an estimated effect of 0.89 extra years in LE. It is worth 
noting that 0.69 years out of total improvement come from mortality changes registered at ages 
over 65. Heart Disease comes second and generated an estimated 0.80 extra years. Conditions of 
the perinatal period also played a central role and caused an estimated increased in the indicator of 




Fig. 5 Changes in LE per CoD and Age, 1985-1998 (Czech Republic, males vs. females) 
 
3.2.3 1999-2013 
From 1998 to 2013 LE in Czech Republic took another big leap (in fact the largest in the entire 
period for males). The increase in LE during this time was 4.02 years for males and 3.09 years for 
females. Despite having registered a lower improvement in mortality at birth, the contributions of 
age groups younger than 65 continue to be the most relevant in the case of males, representing a 
total gain of 2.28 years out of the overall change (or around 57%). In the case of females, the 
changes attributable to these age groups have lost importance in overall terms and amounted to less 
than 36% (over one year) of the total variation. This evidence shows that women were already 
experiencing major mortality improvements in senior ages while men were still experiencing major 
changes in younger age groups. In general terms, Czech Republic men seem to be slowly shifting 
to a pattern that should be more aligned with that of women in the years to come, but this shift 
seems to be happening at a much slower pace than with French men.   
The effects registered per cause of death show subtle differences based on gender. Males increased 
their LE mostly due to improvements in mortality related to Malignant Neoplasms (generating 1.16 
extra years out of which 64% is caused by age groups younger than 65). Heart Diseases also 
contributed greatly (0.89 extra years) whereas Cerebrovascular Diseases came third in importance 
(0.69 extra years).  
For females, the main chapter contributing to changes is Cerebrovascular Diseases (0.93 additional 
years), followed closely by Mortality Chapter X, Other Circulatory Diseases (0.89 years). 
Malignant Neoplasms close the group of the three major contributors, generating an estimated 
increase in LE of 0.67 years. Together these three Mortality Chapters explain 70% of the overall 
improvement in the indicator for males and 82% for females. In Table A.2 in the annex the detailed 




Fig. 6 Changes in LE per CoD and Age, 1999-2013 (Czech Republic, males vs. females) 
 
3.3 Life Expectancy at Birth in the United States of America 
The United States saw their LE grow from 67.02 years for males and 74.65 for females in 1970 to 
76.6 years and 81.3 years in 2013.  One remarkable aspect about these changes is that, out of the 
three countries being studied, U.S. was the country to decrease the most the gender gap during this 
time period. For now, just like in the case of France and Czech Republic, the focus will be placed 
on the sources of changes in LE. 
3.3.1 1970-1984 
LE in the United States experienced a great improvement from 1970 to 1984. The indicator for 
males increased 4.1 years and 3.52 years for females. The most relevant change in mortality, 
attributed to a single age group, was the one registered at age 0, which is responsible for an 
estimated increase in LE of 0.8 and 0.66 years for males and females, respectively. Mortality 
changes at the age groups younger than 65 are responsible for most of the improvement in the 
indicator for this period in both genders, representing a total increase of 3.11 and 2.11 extra years 
of LE for US men and women. In the case of senior ages, the evolution was much less expressive 
during this period and amounted to an improvement in the indicator of 0.98 and 1.4 years, 
respectively.  
A big part of the positive experience in LE in the United States during this period is estimated to 
have come from the country's success in fighting Heart Diseases, generating a reduction in deaths 
high enough to increase LE by 1.47 and 1.25 years for males and females. In the particular case of 
US women, the mortality reductions in Cerebrovascular Diseases and in Conditions of Perinatal 
Period contributed to increase LE by 0.75 and 0.43 years, respectively. For males, a very relevant 
improvement comes from a reduction of deaths related to accidents, homicides, suicides, 
poisonings and the like, which generated an additional 0.74 years of LE. Changes in mortality in 
conditions associated to perinatal period also became a major contributor in case of men. The 





Fig. 7 Changes in LE per CoD and Age, 1970-1984 (USA, males vs. females) 
 
3.3.2 1985-1998 
This period was characterized by more modest increases in LE (2.69 year increase for males and 
1.26 extra years for females). Out of the overall 2.69 additional years estimated for males, 1.66 
years are attributable to mortality improvements registered for ages below 65.  For females, these 
age groups represented 0.84 additional years of LE, out of the total 1.26 years. Because of this, 
during this time period, most improvements in LE are estimated to be generated by these younger 
age groups, representing in both genders over 60% of the overall change.  
In general terms, the major improvement in LE, related to a mortality chapter, was gained in men 
due to a reduction of deaths caused by Heart Diseases (generating an increase of around 1.5 years).  
For females, the attributable effect of Mortality Chapter VIII is also the most relevant (one year in 
this period). Another relevant gain in the indicator is estimated to have happened in the case of 
men, due to a reduction in the death rates associated to Mortality Chapter XX.  
It is worth noting that Mortality Chapter XI, Respiratory Diseases, was responsible for a decrease 
in LE for females in the United States from 1984 to 1998, generating a reduction in the indicator 
of around a quarter of a year. This phenomenon explains a part of the advantage in favor of males 
registered during this period, which - together with the stronger improvement in mortality related 
to heart disease registered for males - explains about 0.75 years of the additional LE gained by US 
men during this period, when compared to women.  
 




In this period, increases in LE reached 2.8 and 1.9 years for males and females. These variations 
are much closer to those registered in 1970-1984. However, during these years, USA seems to have 
entered a new stage in their LE dynamics: one in which LE is driven by mortality improvements in 
senior ages, as treatments and prevention focuses more on retirees and individuals of more 
advanced ages. Mortality improvements in senior age groups are estimated to have contributed with 
1.78 years of additional LE for males and 1.32 years for females. This represents 65% and 69% of 
the overall change and shows a total shift in the pattern found previously. The fight against Heart 
Diseases and Malignant Neoplasms seems to be the main drivers of the increase in LE during this 
new phase. These two mortality chapters are, for both genders, the two main sources of gains. In 
the case of Heart Diseases, they are estimated to have increased LE by 1.25 years for US females 
and 1.36 in the case of males. In the case of Mortality Chapter II, Malignant Neoplasms, the effect 
is very similar for both genders, generating a gain estimated in 0.74 extra years of life for females 
(and 0.77 years for males).  
 
 
Fig. 9 Changes in LE per CoD and Age, 1989-2013 (USA, males vs. females) 
 
The detailed numbers of the decomposition of changes in LE in the USA are presented in Table 
A.3 of the annex. 
  
4. Conclusions 
Judging by the findings in France, Czech Republic and United States, it seems that the evolution 
and increases in LE follows a tendency: improving mortality at birth is clearly an essential first step 
to enhance LE in any country. Once this is achieved, countries move to improve survival at younger 
ages (say ages younger than 65) so that mortality is reduced for these age groups. Finally, they have 
just one way to continue to a more “advanced stage”: once they reach a “high enough” LE, 
improvements start to come from extending the life of seniors and reducing the effects of the 
diseases that affect them the most. It seems that women are the first segment of the population to 
reach this final stage in a country, but males are keeping up, seeing in general terms higher 
improvements in LE. France and United States seemed to be in this stage already for both genders 
by 2013. In the case of Czech Republic, women had reached this level while men still saw most 
increases in LE due to mortality changes in ages younger than 65. 
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Focusing only on four mortality chapters, one could explain at least 60% of the variations in LE in 
the three countries. No matter the geography or gender, it seems that increasing effectiveness to 
reduce mortality related to Heart Diseases, Malignant Neoplasms, Cerebrovascular Diseases and 
External Causes have become the key to maintain increasing levels of LE from 1970 to 2013. In 
the case of French males, the influence of the reduction in mortality rates due to Diseases of the 
Digestive System has also played a major role in this time interval, gaining an estimated 0.89 years 
during the period. In the case of Czech Republic, mortality chapter X has also become a very 
significant source of increases in life expectancy for females (0.90 years). 
On one hand, it is relevant to point out that USA was the country to decrease the most the gender 
gap in LE, reducing the difference in the indicator between males and females in 2.86 years from 
1970 to 2013.  On the other, Czech Republic decreased the gender gap the least out of the three 
country and registered a change of less than a year. This phenomena will be analyzed more in depth 
in a work to follow. 
 
References 
Actuarial Association of Europe, Social Security Sub-Committee of the Pensions Committee 
(2019). Meeting the Challenge of Ageing in the EU, AAE Discussion Paper https://actuary.eu/wp-
content/uploads/2019/03/Meeting-the-challenge-of-ageing-FINAL.pdf.  
 
Agyapong, I. A. et al. (2017). The path to longer and healthier lives for all Africans by 2030: the 
Lancet Commission on the future of health in sub-Saharan Africa. The Lancet, 390, no. 10114, pp. 
2803–2859.  
 
Al-Ramadhan, M. A. (2008). Contributions of age and cause-specific mortality to gains in life 
expectancies among the Kuwait population. Genus, 64: 155–171. 
 
Andreev E., Shkolnikov V., Begun A. (2002). Algorithm for decomposition of differences between 
aggregate demographic measures and its application to life expectancies, healthy life expectancies, 
parity progression ratios and total fertility rates. Demographic Research 7 (14): 499- 522. 
 
Arriaga E. (1984). Measuring and explaining the change in life expectancies. Demography 21(1): 
83-96. 
 
Arriaga, E. (1989). Changing trends in mortality decline during the last decades. In: L. Ruzicka, G. 
Wunsch, P. Kane (Eds.) Differential mortality: Methodological issues and biosocial factors (pp. 
105-129). Oxford: Clarendon Press. 
 
Auger, N., Feuillet, P., Martel, S., Lo, E., Barry, A. D., & Harper, S. (2014). Mortality inequality 
in populations with equal LE: Arriaga’s decomposition method in SAS, Stata, and Excel. Annals 




Auger, N., Harper, S., Barry, A. D., Trempe, N., & Daniel, M. (2012). Life expectancy gap between 
the Francophone majority and Anglophone minority of a Canadian population. European Journal 
of Epidemiology, 27: 27–38. 
 
Bergeron-Boucher, M-P., Ebeling, M & Canudas-Romo, V. (2015) Decomposing changes 
in life expectancy: Compression versus shifting mortality. Demographic Research, 33, 
391–424. 
 
Cause of Death Database. https://cod.mortality.org/.  
 
Chisumpa, V. & Odimegwo, C. (2018). Decomposition of age- and cause-specific adult mortality 
contributions to the gender gap in life expectancy from census and survey data in Zambia. SSM – 
Population Health, 5: 218-226. 
 
Das Gupta, P. (1978). A general method of decomposing a difference between two rates into several 
components. Demography, 15, 99–112. 
 
Hosseinpoor, A. R., Lee, J. H., Lynch, J., Mathers, C., & Abou-Zahr, C. (2012). International 
shortfall inequality in life expectancy in women and men, 1950–2010. Bulletin of World Health 
Organisation, 90. 
 
Khang, Y.-H., Yang, S., Cho, H.-J., Choi-Jung, K., & Yun, S.-C. (2010). Decomposition of 
socioeconomic differences in life expectancy at birth by age and cause of death among 4 million 
South Korean public servants and their dependents. International Journal of Epidemiology, 39, 
1656–1666. 
 
Le, Y., Ren, J., Shen, J., Li, T., & Zhang, C.-F. (2015). The changing gender differences in life 
expectancy in Chinese cities 2005–2010. PLoS ONE, 10, e0123320. 
 
Liu, L. et al. (2016). Global, regional, and national causes of under-5 mortality in 2000–15: an 
updated systematic analysis with implications for the Sustainable Development Goals. The Lancet, 
vol. 388, no. 10063, pp. 3027–3035. 
 
Martikainen, P., Makela, P., Peltonen, R., & Myrskyla, M. (2014). Income differences in life 
expectancy: The changing contribution of harmful consumption of alcohol and smoking. 
Epidemiology, 25, 182–190. 
 
Martikainen, P., Valkonen, T., & Martelin, T. (2001). Change in male and female life expectancy 
by social class: Decomposition by age and cause of death in Finland 1971-95. Journal of 
Epidemiology Community Health, 55, 494–499. 
 
Mondal, N. I., & Shitan, M. (2014). Relative importance of demographic, socioeconomic and health 




Murwirapachena, G. & Mlambo C. (2015) Life Expectancy in Zimbabwe: An Analysis of Five 
Decades. International Business & Economics Research Journal (IBER), 14(3), 417.  
 
Pollard, J. H. (1988). On the decomposition of changes in expectation of life and differentials in 
life expectancy. Demography, 25, 265–276. 
 
Poulant, M., Buettner, D. & Pes, G. (2019). Blue Zones. Reference Module in Biomedical Sciences, 
Elsevier. 
 
Pressat, R. (1985). Contribution des écarts de mortalité par âge à la différance des vies moyennes. 
Population 40(4-5), 766-770. 
 
Ponnapalli, M. K. (2005). A comparison of different methods for decomposition of changes in 
expectation of life at birth and differentials in life expectancy at birth. Demographic Research, 12, 
141–172. 
 
Preston S. H. & Stokes, A. (2012). Sources of Population Aging in More and Less Developed 
Countries. Population and Development Review, 38(2), 221–236.  
 
Rosella, L. C., Calzavara, A., Frank, J. W., Fitzpatrick, T., Donnelly, P. D.  and Henry, D. (2016). 
Narrowing mortality gap between men and women over two decades: a registry-based study in 
Ontario, Canada. BMJ Open, 6(11). [e012564]. https://doi.org/10.1136/bmjopen-2016-012564. 
 
Simmons, S S. (2018). The Gender Gap in Life Expectancy in South Africa from 2000 to 2015: 
The Role of Age-and Cause-Specific Mortality. International Journal of Sciences: Basic and 
Applied Research (IJSBAR) 42(5):24-36. 
 
Shkolnikov, V. M., Andreev, E. M., McKee, M.& Leon, D. A. (2013). Components and possible 
determinants of decrease in Russian mortality in 2004-2010. Demographic Research, 28, 917–950.  
 
Tarkiainen, L., Martikainen, P., Laaksonen, M., & Valkonen, T. (2012). Trends in life expectancy 
by income from 1988 to 2007: Decomposition by age and cause of death. Journal of Epidemiology 
Community Health, 66, 573–578. 
 
Trovato, F., & Heyen, N. B. (2006). A varied pattern of change of sex differential in the G7 
countries. Journal of Biosocial Science, 38, 391–401. 
 
Trovato, F., & Lalu, N. M. (1997). Changing sex differences in life expectancy in Australia between 
1970 and 1990. Journal of the Australian Population Association, 14, 187–200. 
 
Trovato, F., & Odynak, D. (2011). Sex differences in life expectancy in Canada: Immigrant and 




United Nations, Department of Economic and Social Affairs, Population Division (2019). World 
Population Prospects 2019: Press Release. https://population.un.org/wpp/Publications/Files/ 
WPP2019_PressRelease_EN.pdf.  
 
Vaupel, J. W., & Romo, V. C. (2002). Decomposing demographic change into direct vs. 
compositional components. Demographic Research, 7, 1–14. 
 
Wang, H. et al. (2016). Global, regional, and national life expectancy, all-cause mortality, and 
cause-mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden 
of Disease Study 2015. The Lancet, vol. 388, no. 10053, pp. 1459–1544. 
 
Waldon, I. (1983). Sex differences in human mortality. Social Science Medicine, 17, 321–333. 
 
Waldon, I., McCloskey, C., & Earle, I. (2005). Trends in gender differences in accidents mortality: 
Relationships to changing gender roles and other societal trends. Demographic Research, 13, 415–
454. 
 
World Health Organization (2019). World health statistics overview 2019: monitoring health for 




Yang, S., Khang, Y.-H., Chun, H., Harper, S., & Lynch, J. (2012). The changing gender differences 






Table 1 - Decomposition of changes in LE, in years, per mortality chapter (France) 
 
Mortality Chapters 
1970-1984 1984-1998 1998-2013 1970-2013 
Males Females Males Females Males Females Males Females 
I - Infectious diseases 0,1743 0,1324 0,0006 0,0191 0,0402 -0,0065 0,2151 0,1450 
II - Malignant neoplasm -0,5536 0,1482 0,4669 0,3001 1,1388 0,3398 1,0521 0,7881 
III - Other neoplasm 0,0304 0,0342 0,0343 0,0271 -0,0101 0,0105 0,0546 0,0718 
IV-Diseases of blood 0,0029 -0,0119 0,0145 0,0178 0,0423 0,0407 0,0597 0,0466 
V- Endocrine/Nutritional 0,0415 0,1053 0,0289 0,0547 -0,0028 0,0568 0,0676 0,2168 
VI - Mental disorders 0,0138 -0,0444 0,0537 0,0187 -0,0267 -0,0051 0,0408 -0,0308 
VII - Nervous system 0,0866 0,1141 0,0001 -0,0585 -0,0942 -0,1758 -0,0075 -0,1202 
VIII - Heart disease 0,3524 0,5272 0,7238 0,7337 0,8905 0,7844 1,9667 2,0453 
IX - Cerebrovascular disease 0,5097 0,6421 0,4955 0,6651 0,3124 0,4751 1,3176 1,7823 
X - Other circulatory diseases 0,0416 0,0805 0,1244 0,1169 0,1966 0,1447 0,3626 0,3421 
XI - Respiratory diseases 0,3136 0,3125 0,1050 -0,0080 0,4249 0,2843 0,8435 0,5888 
XII - Disease of digestive system 0,2464 0,1927 0,3726 0,2773 0,2797 0,2209 0,8987 0,6909 
XIII - Diseases of the skin -0,0056 -0,0057 0,0019 0,0048 0,0224 0,0364 0,0187 0,0355 
XIV - Diseases of the musculoskeletal system 0,0025 -0,0058 0,0073 0,0198 -0,0064 0,0068 0,0034 0,0208 
XV - Diseases of the genitourinary system 0,1371 0,0985 0,0617 0,0396 0,0438 0,0311 0,2426 0,1692 
XVI - Complications of pregnancy/childbirth 0,0000 0,0222 0,0000 0,0049 0,0100 0,0036 0,0100 0,0307 
XVII - Conditions of perinatal period 0,4930 0,3957 0,0319 0,0220 -0,0087 0,0059 0,5162 0,4236 
XVIII - Congenital malformations 0,1586 0,1380 0,0817 0,0760 0,0371 0,0273 0,2774 0,2413 
XIX - Ill-defined or unknown 0,3800 0,5249 0,3295 0,3316 -0,1064 -0,0525 0,6031 0,8040 
XX - External causes 0,3449 0,1397 0,6456 0,3981 0,8622 0,4721 1,8527 1,0099 
Total increase 2,7701 3,5404 3,5799 3,0608 4,0456 2,7005 10,3956 9,3017 
 




1970-1984 1984-1998 1998-2013 1970-1984 
Males Females Males Females Males Females Males Females 
I - Infectious diseases 0.0911 0.0505 0.0174 0.0308 -0,0882 -0,1046 0,0203 -0,0233 
II - Malignant neoplasm -0.1623 -0.0941 0.3554 0.2376 1,1585 0,6727 1,3315 0,8162 
III - Other neoplasm -0.0020 -0.0005 0.0215 0.0249 -0,0127 -0,0042 0,0068 0,0202 
IV-Diseases of blood -0.0015 0.0019 0.0159 0.0152 -0,0025 -0,0061 0,0118 0,0110 
V- Endocrine/Nutritional 0.0015 0.1112 0.0613 0.1117 -0,042 -0,0372 0,0208 0,1857 
VI - Mental disorders -0.0172 0.0094 0.0206 -0.0009 -0,0451 -0,0505 -0,0417 -0,0420 
VII - Nervous system 0.0259 0.0206 0.0581 0.0458 -0,0463 -0,0252 0,0376 0,0412 
VIII - Heart disease -0.0201 0.2883 1.0996 0.8077 0,8909 0,3888 1,9604 1,4848 
IX - Cerebrovascular disease -0.0866 -0.0689 0.6744 0.8859 0,6877 0,9325 1,2656 1,7495 
X - Other circulatory diseases -0.1019 -0.0290 -0.0140 0.0565 0,6627 0,8868 0,5368 0,9143 
XI - Respiratory diseases 0.4918 0.4265 0.3788 0.2638 0,0529 -0,03 0,9236 0,6603 
XII - Disease of digestive system 0.0491 0.1292 0.0583 0.1012 0,1766 0,0309 0,2639 0,2613 
XIII - Diseases of the skin -0.0001 0.0030 0.0034 0.0029 -0,0093 -0,014 -0,006 -0,0081 
XIV - Diseases of the musculoskeletal system 0.0062 0.0010 0.0020 0.0147 -0,0129 -0,0174 -0,0047 -0,0017 
XV - Diseases of the genitourinary system 0.0458 0.0776 0.2048 0.1374 0,0606 0,074 0,3012 0,2890 
XVI - Complications of pregnancy/childbirth  0.0000 0.0095 0.0000 0.0043 0 -0,0009 0 0,0129 
XVII - Conditions of perinatal period 0.3644 0.3278 0.3701 0.2552 0,098 0,0837 0,8325 0,6667 
XVIII - Congenital malformations -0.0010 0.0102 0.2168 0.2254 0,091 0,0509 0,2969 0,2865 
XIX - Ill-defined or unknown -0.0163 0.0440 -0.0022 0.0137 -0,0964 -0,0128 -0,1149 0,0449 
XX - External causes 0.6333 0.1918 0.1676 0.2564 0,4966 0,2723 1,2876 0,7205 









1970-1984 1985-1998 1999-2013 1970-2013 
Males Females Males Females Males Females Males Females 
I - Infectious diseases 0.0319 0.0225 -0.1847 -0.0595 0.0819 -0.0583 -0.0709 -0.0953 
II - Malignant neoplasm -0.0759 -0.0708 0.3567 0.1757 0.7711 0.7400 1.0519 0.8450 
III - Other neoplasm 0.0058 0.0109 0.0047 0.0052 -0.0154 -0.0115 -0.0050 0.0046 
IV-Diseases of blood -0.0330 0.0007 0.0269 -0.0034 0.0190 0.0004 0.0129 -0.0023 
V- Endocrine/Nutritional 0.0566 0.1378 -0.1100 -0.1036 -0.0141 0.0830 -0.0676 0.1173 
VI - Mental disorders -0.0047 -0.0308 -0.0396 -0.0845 -0.0762 -0.2340 -0.1205 -0.3494 
VII - Nervous system 0.0137 -0.0147 -0.0195 -0.0582 -0.1003 -0.1962 -0.1061 -0.2691 
VIII - Heart disease 1.4720 1.2454 1.5166 1.0075 1.3585 1.2445 4.3471 3.4974 
IX - Cerebrovascular disease 0.4717 0.7503 0.1709 0.1979 0.2149 0.3214 0.8575 1.2696 
X - Other circulatory diseases 0.1397 0.1804 0.0731 0.0461 0.1188 0.0977 0.3316 0.3242 
XI - Respiratory diseases 0.3099 0.1306 0.0344 -0.2431 0.2973 0.1205 0.6417 0.0080 
XII - Disease of digestive system 0.2539 0.1788 0.1286 0.0820 0.0189 -0.0427 0.4014 0.2181 
XIII - Diseases of the skin -0.0028 0.0006 0.0043 0.0068 -0.0002 -0.0037 0.0013 0.0037 
XIV - Diseases of the musculoskeletal system 0.0042 0.0026 -0.0042 -0.0119 -0.0087 0.0044 -0.0087 -0.0050 
XV - Diseases of the genitourinary system 0.0664 0.0625 0.0089 -0.0230 0.0040 -0.0007 0.0792 0.0387 
XVI - Complications of pregnancy/childbirth  0.0000 0.0238 0.0000 -0.0026 0.0000 -0.0202 0.0000 0.0010 
XVII - Conditions of perinatal period 0.5599 0.4336 0.1344 0.1131 0.0442 0.0414 0.7385 0.5882 
XVIII - Congenital malformations 0.0870 0.0897 0.0666 0.0590 0.0474 0.0384 0.2010 0.1870 
XIX - Ill-defined or unknown -0.0008 0.0117 0.1229 0.0689 0.0318 -0.0127 0.1538 0.0679 
XX - External causes 0.7446 0.3543 0.3991 0.0880 -0.0428 -0.2116 1.1009 0.2307 
Total increase 4.1000 3.5199 2.6901 1.2602 2.7500 1.9001 9.5401 6.6802 
 
 
 
